Senescence triggered by the loss of the VHL tumor suppressor

Cell Cycle

Volumn 7, Issue 12, 2008, Pages 1709-1712

  Young, Arthur P ^a,d   Kaelin Jr , William G ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d JOSLIN DIABETES CENTER   (United States)

Author keywords

Hif; p27; p400; Rb; Senescence; Tumor suppression; VHL

Indexed keywords

CANCER SUSCEPTIBILITY; CELL PROLIFERATION; DISEASE COURSE; GENE DELETION; HUMAN; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SENESCENCE; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 47249135044     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.12.6124     Document Type: Review

References (37)

1. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, (eds). Molecular Biology of the Cell. Garland Science: Oxford, United Kingdom 2002.
2. Maronpot RR, Boorman GA, Gaul BW, (eds). Pathology of the Mouse. Cache River Press: Vienna, Illinois 1999.
3. Balmain A. Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell 2002; 108:145-52.
4. Artandi SE, DePinho RA. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 2000; 10:39-46.
5. Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer 2007; 96:1020-4.
6. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-9.
7. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-10.
8. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004; 431:405-6.
9. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest 2007; 117:1175-83.
10. Packman G, Cleveland JL. c-Myc and apoptosis. Biochim Biophys Acta 1995; 1242:11-28.
11. Phillips AC, Vousden KH. E2F-1 induced apoptosis. Apoptosis 2001; 6:173-82.
12. Kopnin BP. Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. Biochemistry (Mosc) 2000; 65:2-27.
13. INK4a. Cell 1997; 88:593-602.
14. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4.
15. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguría A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M. Tumour biology: senescence in premalignant tumours. Nature 2005; 436:642.
16. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T, Schmitt CA. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436:660-5.
17. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436:725-30.
18. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006; 10:459-72.
19. Kaelin WG. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harb Symp Quant Biol 2005; 70:159-66.
20. Kapitsinou PP, Haase VH. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 2008; 15:650-9.
21. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007; 407:8.
22. Kaelin WG Jr. The von hippel-lindau tumor suppressor protein: an update. Methods Enzymol 2007; 435:371-83.
23. Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, Grinberg A, Emmert-Buck MR, Westphal H, Klausner RD, Linehan WM. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 1997; 94:9102-7.
24. Young AP, Schlisio S, Minamishima YA, Zhang Q, Li L, Grisanzio C, Signoretti S, Kaelin WG Jr. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 2008; 10:361-9.
25. Lomb DJ, Straub JA, Freeman RS. Prolyl hydroxylase inhibitors delay neuronal cell death caused by trophic factor deprivation. J Neurochem 2007; 103:1897-906.
26. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002; 13:29-37.
27. Kaelin WG Jr, Ewen ME, Livingston DM. Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product. Mol Cell Biol 1990; 10:3761-9.
28. De Clercq A, Inzé D. Cyclin-dependent kinase inhibitors in yeast, animals and plants: a functional comparison. Crit Rev Biochem Mol Biol 2006; 41:293-313.
29. Kip1. Biochem Biophys Res Commun 2001; 282:853-60.
30. Chan HM, Narita M, Lowe SW, Livingston DM. The p400 E1A-associated protein is a novel component of the p53→p21 senescence pathway. Genes Dev 2005; 19:196-201.
31. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002; 1:459-68.
32. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol 1995; 154:2010-4.
33. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 2001; 98:1583-8.
34. Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 2006; 66:2576-83.
35. Ma W, Tessarollo L, Hong SB, Baba M, Southon E, Back TC, et al. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res 2003; 63:5320-8.
36. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
37. Peeper DS, Shvarts A, Brummelkamp T, Douma S, Koh EY, Daley GQ, Bernards R. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol 2002; 4:148-53.